N-[(2-氯-6-硝基苯基)甲基]甘氨酸乙酯 | 50608-25-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[(2-氯-6-硝基苯基)甲基]甘氨酸乙酯
• 英文名称: N-(2-chloro-6-nitrobenzyl)glycine ethyl ester
• 英文别名: ethyl (2-chloro-6-nitrobenzyl)aminoacetate；ethyl 2-[(2-chloro-6-nitrophenyl)methylamino]acetate
• CAS: 50608-25-8
• 化学式: C₁₁H₁₃ClN₂O₄
• mdl: MFCD19004791
• 分子量: 272.688
• InChiKey: NFLSJYYIIHHOLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[(2-氯-6-硝基苯基)甲基]甘氨酸乙酯 在 镍 TEA 、 氢气 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 20.0 ℃ 、100.0 kPa 条件下， 反应 24.0h， 生成 (5-chloro-2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-Dioxo-1,4-dihydro-2H-2λ⁶-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as Potent and Selective Peptide Deformylase Inhibitors

  摘要：

  Potent, selective, and structurally new inhibitors of the Fe(II) enzyme Escherichia coli peptide deformylase (PDF) were obtained by rational optimization of the weakly binding screening hit (5-chloro-2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-acetic acid hydrazide (1). Three-dimensional structural information, gathered from Ni-PDF complexed with 1, suggested the preparation of two series of related hydroxamic acid analogues, 2-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)hydroxy-acetamides (A) and 2-(2,2-dioxo-1,4-dihydro-2H-2 lambda (6)-benzo[1,2,6] thiadiazin-3-yl)-N-hydroxy-acetamides (B), among which potent PDF inhibitors (37, 42, and 48) were identified. Moreover, two selected compounds, one from each series, 36 and 41, showed good selectivity for PDF over several endoproteases including matrix metalloproteases. However, these compounds showed only weak antibacterial activity.

  DOI：

  10.1021/jm000352g
• 作为产物：
  描述：

  2-氯-6-硝基甲苯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 、 碳酸氢钠 作用下， 以 乙醇 、 乙酸乙酯 、 苯 为溶剂， 生成 N-[(2-氯-6-硝基苯基)甲基]甘氨酸乙酯
  参考文献：
  名称：

  Benzodiazepine derivatives

  摘要：

  本发明提供了以下结构的苯二氮卓类衍生物及其类似物和药学上可接受的盐。本发明的化合物具有优异的抑制活化血凝因子X的效果。这些化合物可用作治疗与活化血凝因子X有关的各种疾病的药剂。

  公开号：

  US20030186969A1

文献信息

• [EN] PROCESS FOR MAKING ANAGRELIDE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ANAGRÉLIDE
  申请人：SYNTHON BV

  公开号：WO2014139572A1

  公开（公告）日：2014-09-18

  The present invention relates to an improved process for making anagrelide of formula (1), or an acid addition salt thereof, including any hydrated or solvated form thereof, comprising reacting a compound of formula (3), or an acid addition salt thereof, (3), wherein R is a C1-C4 alkyl group, with chloroformamidine hydrochloride of formula (8), in an inert solvent, followed by treatment of the reaction mixture with a base.

  本发明涉及一种改进的制备公开的方法，用于制备公开的公式（1）的阿格雷利德，或其酸盐加合物，包括其任何水合物或溶剂化形式，包括将公式（3）的化合物或其酸盐加合物（3）与氯甲酰胺盐酸盐（8）在惰性溶剂中反应，然后用碱处理反应混合物。
• Kienzle; Kaiser; Chodnekar, European Journal of Medicinal Chemistry, 1982, vol. 17, # 6, p. 547 - 556
  作者：Kienzle、Kaiser、Chodnekar

  DOI：——

  日期：——
• PROCESS FOR MAKING ANAGRELIDE
  申请人：Synthon B.V.

  公开号：EP2981537B1

  公开（公告）日：2017-05-10
• Benzodiazepine derivatives
  申请人：AJINOMOTO CO. INC

  公开号：US20030186969A1

  公开（公告）日：2003-10-02

  The present invention provides benzodiazepine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof. The compounds of the present invention have an excellent effect of inhibiting activated blood-coagulation factor X. These compounds are usable as agents for treating various diseases concerned with the activated blood-coagulation factor X. 1

  本发明提供了以下结构的苯二氮卓类衍生物及其类似物和药学上可接受的盐。本发明的化合物具有优异的抑制活化血凝因子X的效果。这些化合物可用作治疗与活化血凝因子X有关的各种疾病的药剂。
• 2-(2-Oxo-1,4-dihydro-2<i>H</i>-quinazolin-3-yl)- and 2-(2,2-Dioxo-1,4-dihydro-2<i>H</i>-2λ⁶-benzo[1,2,6]thiadiazin-3-yl)-<i>N</i>-hydroxy-acetamides as Potent and Selective Peptide Deformylase Inhibitors
  作者：Christian Apfel、David W. Banner、Daniel Bur、Michel Dietz、Christian Hubschwerlen、Hans Locher、Frédéric Marlin、Raffaello Masciadri、Wolfgang Pirson、Henri Stalder

  DOI：10.1021/jm000352g

  日期：2001.6.1

  Potent, selective, and structurally new inhibitors of the Fe(II) enzyme Escherichia coli peptide deformylase (PDF) were obtained by rational optimization of the weakly binding screening hit (5-chloro-2-oxo-1,4-dihydro-2H-quinazolin-3-yl)-acetic acid hydrazide (1). Three-dimensional structural information, gathered from Ni-PDF complexed with 1, suggested the preparation of two series of related hydroxamic acid analogues, 2-(2-oxo-1,4-dihydro-2H-quinazolin-3-yl)hydroxy-acetamides (A) and 2-(2,2-dioxo-1,4-dihydro-2H-2 lambda (6)-benzo[1,2,6] thiadiazin-3-yl)-N-hydroxy-acetamides (B), among which potent PDF inhibitors (37, 42, and 48) were identified. Moreover, two selected compounds, one from each series, 36 and 41, showed good selectivity for PDF over several endoproteases including matrix metalloproteases. However, these compounds showed only weak antibacterial activity.